ACUT Accustem Sciences Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1850767 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-7.2%
TTM EPS YoY8.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-102.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets356.4%
Debt / equity—
Current ratio0.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-27.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $98,400 | — | — | — | — | — | — | — |
| R&D expense | $43,712 | $119,525 | $119,744 | $72,720 | $60,204 | $28,346 | $41,972 | $31,409 |
| SG&A expense | $307,261 | $366,358 | $394,644 | $327,177 | $341,199 | $412,062 | $330,129 | $296,765 |
| Operating income | -$252,573 | -$485,883 | -$514,388 | -$399,897 | -$401,403 | -$440,408 | -$372,101 | -$328,174 |
| Pretax income | — | -$485,883 | -$514,388 | -$399,897 | -$401,403 | -$440,408 | -$372,101 | -$328,174 |
| Net income | -$252,573 | -$485,883 | -$514,388 | -$399,897 | -$401,403 | -$440,408 | -$372,101 | -$328,174 |
| EBITDA | — | — | -$514,388 | -$399,897 | -$401,298 | -$440,095 | -$371,194 | -$327,267 |
| EPS (basic) | -0.02 | -0.03 | — | -0.02 | -0.02 | -0.03 | — | -0.03 |
| EPS (diluted) | -0.02 | -0.03 | — | -0.02 | -0.02 | -0.03 | — | -0.03 |
| Weighted avg. shares (diluted) | 16.07M | 16.07M | — | 16.07M | 16.07M | 12.72M | — | 11.35M |
| Balance sheet | ||||||||
| Cash & equivalents | $12,928 | $12,207 | $13,929 | $14,391 | $31,341 | $36,381 | $5,046 | $37,080 |
| Current assets | $106,204 | $49,532 | $49,446 | $1.57M | $1.61M | $1.55M | $50,433 | $102,494 |
| PP&E, net | — | — | — | — | — | $105 | $418 | $1,325 |
| Total assets | $1.61M | $1.55M | $1.55M | $1.57M | $1.61M | $1.55M | $50,851 | $103,819 |
| Current liabilities | $5.72M | $5.42M | $4.95M | $4.48M | $4.15M | $3.71M | $3.36M | $3.30M |
| Total liabilities | $5.72M | $5.42M | $4.95M | $4.48M | $4.15M | $3.71M | $3.36M | $3.30M |
| Shareholders' equity | -$4.12M | -$3.87M | -$3.40M | -$2.91M | -$2.53M | -$2.16M | -$3.31M | -$3.19M |
| Shares outstanding | 16.07M | 16.07M | 16.07M | 16.07M | 16.07M | 16.07M | 12.10M | 11.35M |
| Cash flow statement | ||||||||
| Operating cash flow | -$248,850 | -$374,176 | $22,357 | -$604,131 | $21,567 | -$290,182 | $414 | -$217,947 |
| Financing cash flow | $249,571 | $372,454 | -$22,820 | $587,181 | -$26,607 | $321,517 | -$32,447 | $208,955 |
| Depreciation & amortization | — | — | $0 | $0 | $105 | $313 | $907 | $907 |
| Stock-based compensation | $7,303 | $15,161 | $23,673 | $0 | $0 | $18,107 | $18,771 | $0 |
Free plan shows the latest 8 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.